On October 7, 2025, Swissmedic announced a recall of specific batches of the veterinary medicinal product Maprelin ad us. vet. 10 ml Injektionslösung für Schweine. This recall affects distribution up to the retail level, emphasizing a need for awareness among veterinary healthcare providers, regulatory specialists, and quality assurance managers.
What changed in the recall?
Swissmedic’s recall involves the following identified batches of Maprelin ad us. vet.:
- 25A061
- 24E075
- 24C291
- 23J034
The recall instructs removal up to the retail level. Affected parties are advised to discontinue distribution or usage of these batches immediately, ensuring all impacted products are securely removed from circulation.
Who is impacted by this recall?
This notice is significant for clinical teams, veterinarians, wholesalers, and retail providers responsible for managing medicinal products for swine. Maprelin is commonly employed in veterinary practices, making the recall critical for ensuring the health and welfare of animals as well as safeguarding regulatory and quality compliance.
Additionally, regulatory affairs specialists and quality professionals must address traceability and compliance aspects arising from this batch recall. These steps are instrumental in minimizing risks associated with the continued presence of these products in the supply chain.
What actions should stakeholders take?
Swissmedic advises affected parties to undertake the following immediate measures:
- Identify and isolate the affected batches from inventory.
- Cease further distribution or use of recalled products.
- Notify relevant team members and institutions handling these medicines.
- Ensure proper documentation and submission of affected batches to the appropriate authority for handling and disposal.
Regulatory compliance teams are encouraged to verify adherence with recall protocols and ensure that all stakeholders are appropriately informed to preclude any non-compliance issues.
Frequently Asked Questions
1. Why has this recall been initiated?
This recall has been executed to mitigate potential risks associated with the identified Maprelin batches. For detailed reasons, stakeholders are advised to consult the official Swissmedic communication.
2. What should I do if I have these batches in stock?
If you possess the listed batches, discontinue their use immediately and follow Swissmedic’s guidance on isolating and returning these products.
3. How can I stay updated on this situation?
Ensure regular monitoring of Swissmedic’s official updates through their website or subscribe to their recall notifications to remain informed about developments.
Conclusion
Swissmedic’s recall underscores the importance of vigilance and accountability in the veterinary domain. Stakeholders are urged to act promptly in isolating and managing the affected Maprelin batches. Proper compliance with recall procedures is vital to ensure the continued safety and integrity of veterinary healthcare systems.
Disclaimer
This article is intended for informational purposes for clinical, regulatory, and quality teams. It does not serve as legal advice. Always consult official Swissmedic channels for binding guidance.
Swissmedic Announcement
For full information about the Swissmedic announcement, see the link below.